GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (STU:7NS0) » Definitions » EV-to-EBIT

Palisade Bio (STU:7NS0) EV-to-EBIT : 0.46 (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Palisade Bio's Enterprise Value is €-5.76 Mil. Palisade Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-12.46 Mil. Therefore, Palisade Bio's EV-to-EBIT for today is 0.46.

The historical rank and industry rank for Palisade Bio's EV-to-EBIT or its related term are showing as below:

STU:7NS0' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.18   Med: 0.68   Max: 0.91
Current: 0.46

During the past 4 years, the highest EV-to-EBIT of Palisade Bio was 0.91. The lowest was -0.18. And the median was 0.68.

STU:7NS0's EV-to-EBIT is ranked better than
80.33% of 422 companies
in the Biotechnology industry
Industry Median: 10.345 vs STU:7NS0: 0.46

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Palisade Bio's Enterprise Value for the quarter that ended in Mar. 2024 was €-5.86 Mil. Palisade Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-12.46 Mil. Palisade Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 212.47%.


Palisade Bio EV-to-EBIT Historical Data

The historical data trend for Palisade Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisade Bio EV-to-EBIT Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- -0.34 -0.23 0.54

Palisade Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 0.30 0.73 0.54 0.45

Competitive Comparison of Palisade Bio's EV-to-EBIT

For the Biotechnology subindustry, Palisade Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palisade Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palisade Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Palisade Bio's EV-to-EBIT falls into.



Palisade Bio EV-to-EBIT Calculation

Palisade Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-5.761/-12.456
=0.46

Palisade Bio's current Enterprise Value is €-5.76 Mil.
Palisade Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Palisade Bio  (STU:7NS0) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Palisade Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-12.456/-5.86237
=212.47 %

Palisade Bio's Enterprise Value for the quarter that ended in Mar. 2024 was €-5.86 Mil.
Palisade Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Palisade Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Palisade Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Palisade Bio (STU:7NS0) Business Description

Traded in Other Exchanges
Address
5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008
Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Palisade Bio (STU:7NS0) Headlines

No Headlines